Description: Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.
Home Page: www.sareum.com
SAR Technical Analysis
Langford Arch
Cambridge,
CB22 3FX
United Kingdom
Phone:
44 1223 497 700
Officers
| Name | Title |
|---|---|
| Dr. Tim J. Mitchell Ph.D. | Founder, CEO & Exec. Director |
| Dr. John C. Reader Ph.D. | Founder, Chief Scientific Officer & Exec. Director |
| Mr. Anthony Bunn F.C.M.A., FCMA | Sec. |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.1805 |
| Price-to-Sales TTM: | 4491.973 |
| IPO Date: | 2004-10-11 |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |